China's medical products administrator approved Innovent Biologics' (HKG:1801) limertinib for a mutation of locally advanced or metastatic non-small cell lung cancer, according to a Friday filing with the Hong Kong Exchange.
The drug is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.
It is indicated for the EGFR T790M mutation, which is the most common mutation and affects up to 50% of Asian patients of the disease, the filing said.
Shares rose 3% during Friday's late morning trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。